SAHPRA SAPC Regulatory Enforcement: Addressing Unregistered GLP-1 and GIP Products

SAHPRA SAPC regulatory enforcement has intensified following the seizure of all GLP-1 and GIP injectable products at iDexis (Pty) Ltd trading as Sentra Pharmacy. An inspection on 11 May 2026 revealed the facility was manufacturing and distributing unregistered medicines containing semaglutide, tirzepatide, or their combination under the guise of compounding, breaching the Medicines and Related Substances Act, 101 of 1965. These actions followed evidence of illegal active pharmaceutical ingredient importation, absent quality controls, and adverse event reports including hospitalizations.

Seizure Targets Illegal Compounding

Inspection findings documented multiple critical failures, such as the lack of analytical testing for identity, potency, and purity; inadequate sterile conditions without a functional HVAC system; and the absence of any pharmacovigilance framework. The allocated production room failed to meet requirements for aseptic preparations, elevating contamination risks for products promoted for weight management. These documented shortcomings directly support the decision to mandate a full recall of distributed stock through healthcare providers and pharmacies.

Legal Boundaries Enforced

Under the Medicines and Related Substances Act, compounding remains confined to individualized preparations based on valid prescriptions and cannot extend to large-scale manufacture, advertising, or distribution of unregistered medicines. The joint SAHPRA-SAPC investigation confirmed that Sentra Pharmacy operated outside these boundaries by marketing GLP-1 and GIP formulations broadly, prompting enforcement that includes potential disciplinary measures against involved pharmacy professionals, up to removal from the register. This SAHPRA SAPC regulatory enforcement reinforces the statutory limits that separate legitimate patient-specific preparation from unlawful commercial activity.

Market Access Risks Highlighted

The seizure and recall actions highlight vulnerabilities in supply chains for high-demand therapies, potentially affecting product quality. Unlawful distribution channels may distort pricing and reimbursement negotiations by introducing unverified alternatives that carry documented safety liabilities, thereby increasing downstream healthcare utilization from adverse events.